Breaking News

Actavis to Divest Pharmatech to TPG

TPG plans to grow the business while Actavis aims to focus on Global Supply Chain Network

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Actavis plc and TPG, a global private investment firm, have entered a definitive agreement under which Actavis will divest its Aptalis Pharmaceutical Technologies (Pharmatech) business, which operates within Actavis’ subsidiary in the U.S., Canada and Europe. Financial terms were not disclosed.    Pharmatech provides R&D and manufacturing services, with specialized capabilities in taste-masking and customized drug release and supports projects from formulation through scale-up and commercial...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters